百令胶囊与胰激肽原酶联合治疗早期糖尿病肾病的临床观察

目的 观察百令胶囊与胰激肽原酶联合治疗早期糖尿病肾病（EDN）的疗效以及治疗前后尿微量白蛋白的变化.方法 将50例早期EDN患者随机分为两组,对照组在常规治疗基础上予胰激肽原酶240 U,3次/d,口服;联合治疗组在对照组基础上加用百令胶囊1.0 g,3次/d,口服,12周和6个月后观察联合治疗组与对照组治疗前后24 h尿微量白蛋白排泄率（UAER）的变化.结果 治疗后12周,两组患者治疗前后24 h UAER均有较明显下降（P＜0.05）;治疗后6个月,对照组患者治疗前后24 h UAER有一定的下降（P＜0.05）,联合组患者治疗前后24 h UAER有明显的下降（P＜0.01）;治疗后12周和6个月组间比较,联合组24 h UAER与对照组比较差异有统计学意义（P＜0.05）.结论 百令胶囊与胰激肽原酶联合应用能明显降低EDN患者的尿微量白蛋白排泄,可以有效延缓DN的进展.

Therapeutic efficacy of bailing capsule combined with pancreatic kininogenase in the treament of early diabetic nephropathy

Objective To observe the therapeutic efficacy of bailing capsule combined with pancreatic kininogenase（PK） in the treatment of early diabetic nephropathy （EDN）, and the changes of urinary micro-albumin. Methods Fifty cases of EDN were randomly divided into two groups. On the bases of routine therapy, the comparison group took PK 240 U, 3 times a day orally. On the basis of the comparison group ,the combined treatment group took bailing eapstde 1.0 g, 3 times a day orally. The changes of 24 h urinary albumin excretion rate（UAER） in the combined treatment group and the comparison group were observed before and after 12 weeks or 6 months of treatment. Results The 24h UAER of the two groups were all decreased（P 〈0. 05） after 12 weeks;after 6 months,the 24 h UAER of the comparison group were decreased（P 〈 0. 05）, and that of the combined treatment group decreased more significantly（P 〈0. 01 ） ;there was significant difference between the two groups after 12 weeks or 6 months of treatment（P 〈 0. 05）. Conclusion Bailing capsule combined with PK could significantly reduced urinary micro-albumin excretion of EDN patients and effectively delay the progress of DN.